- Home
- BPTH vs QNRX Comparison
BPTH vs QNRX Comparison
Compare BPTH & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BPTH
- QNRX
- Stock Information
- Founded
- BPTH 2007
- QNRX 2018
- Country
- BPTH United States
- QNRX United States
- Employees
- BPTH N/A
- QNRX N/A
- Industry
- BPTH Biotechnology: Pharmaceutical Preparations
- QNRX Medical/Dental Instruments
- Sector
- BPTH Health Care
- QNRX Health Care
- Exchange
- BPTH Nasdaq
- QNRX Nasdaq
- Market Cap
- BPTH 4.8M
- QNRX 4.8M
- IPO Year
- BPTH N/A
- QNRX N/A
- Fundamental
- Price
- BPTH $0.73
- QNRX $0.31
- Analyst Decision
- BPTH Strong Buy
- QNRX Strong Buy
- Analyst Count
- BPTH 2
- QNRX 1
- Target Price
- BPTH $30.00
- QNRX $4.00
- AVG Volume (30 Days)
- BPTH 161.7K
- QNRX 4.1M
- Earning Date
- BPTH 03-07-2025
- QNRX 03-12-2025
- Dividend Yield
- BPTH N/A
- QNRX N/A
- EPS Growth
- BPTH N/A
- QNRX N/A
- EPS
- BPTH N/A
- QNRX N/A
- Revenue
- BPTH N/A
- QNRX N/A
- Revenue This Year
- BPTH N/A
- QNRX N/A
- Revenue Next Year
- BPTH N/A
- QNRX N/A
- P/E Ratio
- BPTH N/A
- QNRX N/A
- Revenue Growth
- BPTH N/A
- QNRX N/A
- 52 Week Low
- BPTH $0.59
- QNRX $0.28
- 52 Week High
- BPTH $10.00
- QNRX $6.18
- Technical
- Relative Strength Index (RSI)
- BPTH 37.30
- QNRX 31.40
- Support Level
- BPTH $0.78
- QNRX $0.28
- Resistance Level
- BPTH $0.84
- QNRX $0.38
- Average True Range (ATR)
- BPTH 0.05
- QNRX 0.07
- MACD
- BPTH -0.02
- QNRX -0.02
- Stochastic Oscillator
- BPTH 4.05
- QNRX 6.12
About BPTH Bio-Path Holdings Inc.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.